US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

152.12

+0.90000.60%

Volume:27.65K

Turnover:4.22M

Market Cap:2.19B

PE:-31.06

High:154.05

Open:152.54

Low:150.96

Close:151.22

52wk High:161.38

52wk Low:54.28

Shares:14.41M

Float Shares:8.40M

Volume Ratio:0.82

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:10.11

PE(LYR):-41.03

Loading ...

Overview Company News Filings

Palvella Therapeutics Announces New Data From the Phase 2 Toiva Trial of Qtorin™ Rapamycin in Cutaneous Venous Malformations Presented at the 83Rd Annual Meeting of the Society for Investigative Dermatology

THOMSON REUTERS

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics moves Nasdaq listing to Global Market from Capital Market

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

THOMSON REUTERS

Palvella Therapeutics Initiated at Overweight by Stephens & Co.

Palvella Therapeutics Inc : Stephens Initiates Coverage With Overweight Rating; Target Price $220

THOMSON REUTERS

Palvella Therapeutics initiated with an Overweight at Stephens

Stock Track | Palvella Therapeutics Soars 6.05% Intraday on Positive Analyst Ratings

Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating

MT Newswires Live

Palvella Therapeutics (PVLA) Receives a Buy from Oppenheimer

Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year

Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Palvella Therapeutics, Inc Q1 EPS USD -1.2

THOMSON REUTERS

Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share

MT Newswires Live

Palvella Q1 net loss widens to $15.8 million; R&D expenses rise to $9.3 million

Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate

Benzinga Earnings

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas

Palvella doses first patients in Phase 2 LOTU trial of QTORIN rapamycin gel

Palvella Therapeutics Inc - Topline Results From Phase 2 Lotu Trial Expected in Second Half of 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PVLA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":152.12,"timestamp":1789569234532,"preClose":151.22,"halted":0,"volume":27645,"delay":0,"changeRate":0.005951593704536475,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Trading","change":0.9,"latestTime":"09-16 10:34:11 EDT","open":152.54,"high":154.05,"low":150.96,"amount":4216997.6037,"amplitude":0.020434,"askPrice":152.39,"askSize":16,"bidPrice":151.88,"bidSize":32,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":151.22,"preHourTrading":{"tag":"盘前","latestPrice":151.41,"preClose":151.22,"latestTime":"07:16 EDT","volume":47,"amount":7084.52056,"timestamp":1789557378813,"change":0.19,"changeRate":0.001256,"amplitude":0.039611},"postHourTrading":{"tag":"盘后","latestPrice":151.2,"preClose":151.22,"latestTime":"19:30 EDT","volume":6067,"amount":917460.66,"timestamp":1789515005890,"change":-0.02,"changeRate":-0.000132,"amplitude":0.000132},"volumeRatio":0.815069,"impliedVol":0.5208,"impliedVolPercentile":0.1036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":0.815069,"shares":14408407,"dividePrice":0,"high":154.05,"amplitude":0.020434,"preClose":151.22,"low":150.96,"week52Low":54.28,"pbRate":"10.11","week52High":161.38,"institutionHeld":0,"latestPrice":152.12,"committee":0.333333,"eps":-4.897784,"divideRate":0,"volume":27645,"delay":0,"ttmEps":-4.897784,"open":152.54,"prevYearClose":104.67,"prevWeekClose":150.13,"prevMonthClose":152.59,"prevQuarterClose":152.82,"fiveDayClose":151.34,"twentyDayClose":150.42,"sixtyDayClose":118.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778558400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-09-15","current":-31.058944,"percent":0.264368,"low":-60.48704,"twenty":-36.721634,"median":-28.616757,"eighty":-11.11329,"high":46.119317,"avg":-20.144907,"sd":24.197685,"marketCap":2185611257},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-09-04","current":-36.30827,"twenty":-36.860843,"median":-28.502544,"eighty":-11.000041,"marketCap":2240075036},{"date":"2026-09-11","current":-35.121893,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"marketCap":2166880328},{"date":"2026-09-15","current":-35.425494,"twenty":-36.721634,"median":-28.616757,"eighty":-11.11329,"marketCap":2185611257}],"updateTime":1789569251575},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635608089","title":"Palvella Therapeutics Announces New Data From the Phase 2 Toiva Trial of Qtorin™ Rapamycin in Cutaneous Venous Malformations Presented at the 83Rd Annual Meeting of the Society for Investigative Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA5HKHSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089195","title":"Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089195","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089195?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295760/0/en/Palvella-Therapeutics-Announces-New-Data-from-the-Phase-2-TOIVA-Trial-of-QTORIN-Rapamycin-in-Cutaneous-Venous-Malformations-Presented-at-the-83rd-Annual-Meeting-of-the-Society-for-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4139","SID","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635890327","title":"Palvella Therapeutics moves Nasdaq listing to Global Market from Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2635890327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635890327?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:31","pubTimestamp":1778671916,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics transferred listing of its common stock to Nasdaq Global Market from Nasdaq Capital Market, effective at Wednesday open.Move follows company meeting higher-tier listing standards tied to financial metrics, public float, liquidity, and corporate governance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL21LKj5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014013.SGD","NDAQ","BK4112","LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","PVLA","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635578921","title":"Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2635578921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635578921?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nFWN41Q16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634621202","title":"Palvella Therapeutics Initiated at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634621202","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634621202?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:33","pubTimestamp":1778592780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 09:33 ET (13:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634459297","title":"Palvella Therapeutics Inc : Stephens Initiates Coverage With Overweight Rating; Target Price $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2634459297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634459297?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:18","pubTimestamp":1778581112,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291072","title":"Palvella Therapeutics initiated with an Overweight at Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634291072?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:20","pubTimestamp":1778577610,"startTime":"0","endTime":"0","summary":"Stephens initiated coverage of Palvella Therapeutics (PVLA) with an Overweight rating and $220 price target Palvella is a clinical-stage biopharmac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-overweight-at-stephens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-overweight-at-stephens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111098490","title":"Stock Track | Palvella Therapeutics Soars 6.05% Intraday on Positive Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1111098490","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111098490?lang=en_us&edition=fundamental","pubTime":"2026-05-09 02:14","pubTimestamp":1778264070,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics' stock surged 6.05% during intraday trading on Friday, driven by a wave of positive analyst sentiment.Multiple Wall Street analysts expressed bullish views on the healthcare...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633454373","title":"Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2633454373","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633454373?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:28","pubTimestamp":1778246909,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $228.81, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633513644","title":"Palvella Therapeutics (PVLA) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633513644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633513644?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:58","pubTimestamp":1778245109,"startTime":"0","endTime":"0","summary":"In a report released today, Trevor Allred from Oppenheimer maintained a Buy rating on Palvella Therapeutics, with a price target of $210.00. Allred...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4139","PVLA","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175859","title":"Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175859?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:22","pubTimestamp":1778181727,"startTime":"0","endTime":"0","summary":"Reports Q1 cash, cash equivalents and short-term investments were $261.9M as of March 31, 2026. Reports Q1 R&D expenses $9.3M vs $4.1M last year. R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-q1-eps-1-20-vs-74c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-q1-eps-1-20-vs-74c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128798","title":"Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128798","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128798?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:38","pubTimestamp":1778161090,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryPalvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of $1.20 per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141573","title":"Palvella Therapeutics, Inc Q1 EPS USD -1.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141573?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:51","pubTimestamp":1778154691,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX9F2378:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633268149","title":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633268149","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633268149?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:38","pubTimestamp":1778153886,"startTime":"0","endTime":"0","summary":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633499361","title":"Palvella Q1 net loss widens to $15.8 million; R&D expenses rise to $9.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633499361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633499361?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:34","pubTimestamp":1778153659,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics posted a Q1 net loss of $15.8 million, or $1.20 per share, widening from a $8.2 million loss a year earlier.Research and development expense rose to $9.3 million from $4.1 million, while general and administrative costs climbed to $5.5 million from $3.8 million.Cash, cash equivalents and short-term investments totaled $261.9 million as of March 31, reflecting net proceeds of $215.8 million from a February equity financing.FDA granted a pre-NDA meeting for QTORIN rapamycin in microcystic lymphatic malformations, expected in Q2 2026, with NDA submission still targeted for the second half.Management said it sees potential approval and U.S. commercial launch for QTORIN rapamycin in the first half of 2027 following positive Phase 3 SELVA topline results.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5MgYS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014021.USD","BK4588","PVLA","BK4585","SG9999014039.USD","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633493821","title":"Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633493821","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633493821?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153452,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over losses of $(0.74) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52361425/palvella-therapeutics-q1-eps-1-20-misses-0-93-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149448","title":"Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149448?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"FDA Pre-New Drug Application (NDA) meeting granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289863/0/en/Palvella-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930284","title":"BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930284","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930284?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:36","pubTimestamp":1777894586,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin Rapamycin For Clinically Significant AngiokeratomasMay 4 (Reuters) - Palvella Therapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUACMSQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632893013","title":"Palvella doses first patients in Phase 2 LOTU trial of QTORIN rapamycin gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2632893013","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632893013?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:31","pubTimestamp":1777894307,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics began dosing first patients in LOTU, a Phase 2 trial testing topical QTORIN rapamycin gel for clinically significant angiokeratomas, a rare condition with no FDA-approved treatments.Study reads out in second half of 2027, with no results reported yet.Trial aims to show safety and clinical improvement versus baseline, targeting symptoms that drive bleeding risk, infection risk, and quality-of-life burden.Program carries FDA Fast Track status, supporting a faster development path if Phase 2 data are positive.Management framed angiokeratomas as a meaningful commercial opportunity, citing more than 50,000 diagnosed patients in US.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL6ncqNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","BK4139","PVLA","BK4585","SG9999014021.USD","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4112","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930972","title":"Palvella Therapeutics Inc - Topline Results From Phase 2 Lotu Trial Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930972?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:30","pubTimestamp":1777894201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUACMSQV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":136,"code":"91000000","status":"200"}]}}